CORONA Remedies share news, announcements and annual reports
NSE: CORONABSE: 544644Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,217.40.
30 Oct: open ₹2,217.40, high ₹2,237.40, low ₹2,090.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,147 Cr566th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 63.51
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 16.33
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 28.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 31.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.12
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 23,61838.1% delivered
CORONA Remedies has 73 announcements on record, routine notices left out; 7 in the 30 days to 2 Nov 2026, the latest on 31 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.CORONA Remedies quarterly results
The board met on 30 Oct 2026 to consider financial results
Notice filed 16 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
CORONA Remedies annual reports, presentations and earnings calls
The company's own documents, latest first.CORONA Remedies financials, year by year
Annual reports1
- Annual report, year to Mar 202615 Jun 2026
Investor presentations5
- Investor Presentation30 Oct 2026
- Investor Presentation31 Jul 2026
- Presentation11 May 2026
- Investor Presentation2 Feb 2026
- Investor Presentation3 Jan 2026
Earnings calls8
- Transcript10 Aug 2026
- Link of Recording3 Aug 2026
- Transcript18 May 2026
- Link of Recording12 May 2026
- Transcript10 Feb 2026
3 earlier call documents
- Link of Recording3 Feb 2026
- Transcript12 Jan 2026
- Link of Recording5 Jan 2026
CORONA Remedies share news and announcements
Newest first. Page 1 of 2.
Oct 2026
31 Oct · Analysts
30 Oct · Results
16 Oct · Analysts
16 Oct · Board meeting
Sep 2026
30 Sep · Rating
18 Sep · Analysts
9 Sep · Legal
The exchange asked on 9 Sep 2026
Aug 2026
20 Aug · Analysts
10 Aug · Analysts
7 Aug · Updates
Jul 2026
31 Jul · Results
22 Jul · Analysts
17 Jul · Board meeting
9 Jul · Meeting
Jun 2026
30 Jun · Commencement of commercial production/operations
15 Jun · Updates
10 Jun · Analysts
3 Jun · Analysts
1 Jun · Analysts
May 2026
19 May · Analysts
Apr 2026
30 Apr · Analysts
Mar 2026
7 Mar · Analysts
Feb 2026
27 Feb · Analysts
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 1 Oct 2026Credit ratingdown 3.06%−2.1 pts vs Nifty 500market median 0.0% · five sessions −4.8% (−2.7 pts vs Nifty 500) · volume 0.4× usual · delivery +1.6 pts against usual · The announcement
- 3 Aug 2026Resultsup 0.33%−1.1 pts vs Nifty 500market median −0.7% · five sessions −1.9% (−3.0 pts vs Nifty 500) · volume 4.4× usual · delivery −11.8 pts against usual · The announcement
- 12 May 2026Dividenddown 7.10%−4.9 pts vs Nifty 500market median 0.0% · five sessions +3.7% (+5.1 pts vs Nifty 500) · volume 9.4× usual · delivery −16.0 pts against usual · The announcement
- 12 May 2026Board or managers changeddown 7.10%−4.9 pts vs Nifty 500market median 0.0% · five sessions +3.7% (+5.1 pts vs Nifty 500) · volume 9.4× usual · delivery −16.0 pts against usual · The announcement
- 3 Feb 2026Resultsup 2.89%+0.2 pts vs Nifty 500market median −0.7% · five sessions +12.1% (+8.3 pts vs Nifty 500) · volume 0.6× usual · delivery −10.8 pts against usual · The announcement
- 3 Feb 2026Credit ratingup 2.89%+0.2 pts vs Nifty 500market median 0.0% · five sessions +12.1% (+8.3 pts vs Nifty 500) · volume 0.6× usual · delivery −10.8 pts against usual · The announcement
- 5 Jan 2026Resultsup 1.63%+1.8 pts vs Nifty 500market median −0.7% · five sessions −0.9% (+1.7 pts vs Nifty 500) · delivery −8.8 pts against usual · The announcement
CORONA Remedies results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.